scholarly journals Albumin excretion rate in mild hypertension: a 5-year follow-up of the harvest study

2000 ◽  
Vol 13 (6) ◽  
pp. S292-S293
Author(s):  
P Mormino
Keyword(s):  
Mild Hypertension ◽  
Excretion Rate ◽  
Albumin Excretion Rate ◽  
Albumin Excretion

Glycosaminoglycans as a Possible Tool for Micro- and Macroalbuminuria in Diabetic Patients. A Pilot Study

1997 ◽  
Vol 25 (2) ◽  
pp. 81-86 ◽  
Author(s):  
G Sorrenti ◽  
M Grimaldi ◽  
N Canova ◽  
E Palazzini ◽  
N melchionda
Keyword(s):  
Type Ii Diabetes ◽  
Excretion Rate ◽  
Albumin Excretion Rate ◽  
Favourable Effect ◽  
Diabetic Patients ◽  
Type Ii ◽  
Therapeutic Tool ◽  
Albumin Excretion ◽  
End Of Treatment

The aim was to investigate sulodexide as a possible therapeutic tool for treating micro- and macroalbuminuria in diabetic patients. Fifteen patients (13 micro- and 2 macroalbuminuric) with Type II diabetes, were treated with 600 lipoprotein-lipase releasing units of sulodexide by the intramuscular route, daily for 28 days, and followed up for 2 months. The main evaluation parameter was the albumin excretion rate. At the end of treatment, six of the 13 microalbuminuric patients showed a decrease in the albumin excretion rate, which increased again in three of the six during follow-up. In the two macroalbuminuric patients the albumin excretion rate decreased at the end of treatment and remained unchanged after a further 2 months. Overall analysis (15 patients) showed a significant decrease ( P < 0.05) in the albumin excretion rate compared with baseline. Metabolic control and blood pressure remained unchanged during the entire period of study. No adverse events were registered. It is concluded that sulodexide administration has a favourable effect in reducing the albumin excretion rate in Type II diabetic patients with micro- and macroalbuminuria.

Medium-term follow-up of renal function in hypoxaemic congenital heart disease patients

2015 ◽  
Vol 26 (6) ◽  
pp. 1137-1143 ◽  
Author(s):  
Efrén Martínez-Quintana ◽  
Fayna Rodríguez-González
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Arterial Hypertension ◽  
Congenital Heart ◽  
Excretion Rate ◽  
Analytical Data ◽  
Albumin Excretion Rate ◽  
Albumin Excretion ◽  
Pulmonary Arterial

AbstractIntroductionHypoxaemic congenital heart disease (CHD) patients are at higher risk of complications. The aim of this study was to compare and follow-up blood and 24-hour urine analytical data in hypoxaemic and non-hypoxaemic CHD patients.MethodsThe inclusion criteria for this study were as follows: patients older than 14 years of age with a structural CHD with or without associated hypoxaemia.ResultsIn total, 27 hypoxaemic and 48 non-hypoxaemic CHD patients were included in order to compare blood and 24-hour urine analytical data. Among hypoxaemic patients, 13 (48.1%) were male, two (7.4%) had diabetes mellitus, one of whom was a smoker, one (3.7%) had systemic arterial hypertension, and 11 (40.7%) showed pulmonary arterial hypertension. The mean follow-up time was 3.1±1.9 years. Hypoxaemic CHD patients showed higher proteinuria concentrations (g/24 hours) (0.09 (0.07; 0.46) versus 0.08 (0.07; 0.1), p=0.054) and 24-hour albumin excretion rate (µg/min) (16.5 (11.2; 143.5) versus 4.4 (0.0; 7.6), p<0.001) compared with non-hypoxaemic CHD patients; however, no significant differences were found in the proteinuria levels and in the 24-hour albumin excretion rate in CHD patients with associated hypoxaemia, both at baseline and at follow-up. When divided into groups, hypoxaemic patients with palliative shunts showed significantly higher proteinuria concentrations compared with hypoxaemic patients not operated on or with Fontan procedures (p=0.01). No significant differences were seen in 24-hour proteinuria and 24-hour albumin excretion rate during the follow-up of patients with palliative shunts.ConclusionsHypoxaemic CHD patients have significant higher 24-hour proteinuria concentration and 24-hour albumin excretion rate compared with non-hypoxaemic CHD patients. Among hypoxaemic CHD patients, those with palliative shunts showed the highest 24-hour proteinuria concentrations.

scholarly journals Best Albuminuria Measurement to Predict Cardiovascular and Renal Events

2016 ◽  
Vol 43 (5) ◽  
pp. 383-388 ◽  
Author(s):  
Lucie Bauer ◽  
Insa E. Emrich ◽  
John W. Pickering ◽  
Kathrin Untersteller ◽  
Franziska Sandermann ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Cardiovascular Events ◽  
Albumin Excretion Rate ◽  
Primary Analysis ◽  
Home Study ◽  
Spot Urine ◽  
Albumin Excretion ◽  
Net Reclassification Improvement ◽  
Kdigo Guidelines

Background: Kidney Disease Improving Global Outcomes (KDIGO) guidelines encourage clinicians to estimate 24-hour albuminuria as albumin to creatinine ratio (ACR) from spot urine samples. However, ACR underestimates 24-hour albumin excretion in muscular individuals. Equations that adjust ACR for surrogates of muscle mass to yield an estimated albumin excretion rate (eAER) were developed. We hypothesised that eAER is a better predictor of cardiovascular and renal outcomes than ACR. Methods: We determined ACR and eAER among 443 patients with chronic kidney disease G2-G4 recruited into the CARE FOR HOMe study. Patients were classified into KDIGO albuminuria categories, and followed for cardiovascular and renal events. The primary analysis was the net reclassification improvement (NRI) for those with and without events within 3 years of follow-up. Results: Eighty five patients experienced cardiovascular events during 3 years of follow-up, 13 of whom were reclassified to a more advanced albuminuria category, and 1 patient to a less advanced category by eAER compared to ACR (NRIevent: 14.1% (95% CI 5.8-22.4)). Among 358 patients without a cardiovascular event, 17 patients were reclassified to a more advanced albuminuria category, and 2 patients to a less advanced category by eAER (NRIno event: -4.2%, 95% CI -8.5 to -1.8). Sixty patients went through renal events, and 383 patients had event-free 3-year follow-up. NRIevent was 6.7% (95% CI -1.2 to 14.5), and NRIno event was -6.0% (95% CI -10.6 to 3.4) for renal events. Conclusion: Compared to ACR albuminuria categories, eAER categories are better associated with future cardiovascular events, but not with renal events.

scholarly journals The expression of POMC and AgRP in brain and kidney tissues at different stages of diabetic nephropathy rats

2021 ◽  
Vol 1 (1) ◽  
pp. 43-49
Author(s):  
Shasha Liu ◽  
Jingjing Da ◽  
Jiayu Li ◽  
Rong Dong ◽  
Jing Yuan ◽  
...  
Keyword(s):  
Body Weight ◽  
Diabetic Nephropathy ◽  
Blood Glucose ◽  
Urinary Albumin Excretion ◽  
Excretion Rate ◽  
Kidney Tissue ◽  
Albumin Excretion Rate ◽  
Urinary Albumin ◽  
Urinary Albumin Excretion Rate ◽  
Albumin Excretion

Abstract Objective To explore the changes of proopiomelanocortin (POMC) and Agouti-Related Peptide (AgRP) expression in brain and kidney tissues under insulin intervention at different stages of diabetic nephropathy (DN) rats. Methods The male Sprague-Dawley (SD) rats of DN were treated with high-fat diet for 8 weeks and induced by intraperitoneally injection of streptozotocin (30 mg/kg) for one time. Then DN rats were also injected insulin subcutaneously at 2–5 U/(kg·24 h) from initiation of the streptozotocin. Kidney tissue, blood sample, and 24 h-urine were collected to detect the ratio of kidney/body weight, blood glucose and 24-h urinary albumin excretion rate at different stages (4, 8, 12, and 16 weeks). Immunohistochemistry assay was used to measure the expression of POMC and AgRP at different stages of DN rats. Results The DN rats were established successfully. With the progression of DN, blood glucose, 24-h urinary albumin excretion rate and kidney body weight ratio increased significantly, while decreased when insulin was injected. Immunohistochemistry showed that the expression levels of POMC were decreased gradually in brain and kidney tissues. Conversely, the expression of AgRP in kidney was highest at week 8 and then decreased gradually. The effect of insulin on normalizing POMC and AgRP expression in brain and renal tissues was also observed in DKD rats. Conclusion With the progression of DN, the expression of POMC and AgRP in kidney tissues was observed at different stages of disease, and their expressions were significantly normalized by insulin. The mechanism of in situ expression of POMC and AGRP in kidney to the progression of DN needs further investigations.

Sign in / Sign up

Export Citation Format

Share Document